Milan Sheth, DO
Interventional Cardiology · Oak Ridge, TNNPI 1619198306
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,063 of the $23,238 with a category attached, or 77.7%. 24 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 32.6% of the total. Reporting peaked in 2019 at $12,591 and has fallen 98.7% since, to $164 in 2025.
Across 192 payments — averaging $121.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$8K
- Pfizer$7K
- AstraZeneca$5K
- Boston Scientific$2K
- Lilly USA, LLC$622
- Novartis$555
- plus $2K from 18 others
Across 15 payments — averaging $11,735 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$169K
- E.r. Squibb & Sons, L.L.C.$7K
What the payments were for
- Speaking & faculty fees$18,06378%
- Travel & lodging$1,5677%
- Food & beverage$3,46415%
- Education$1451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $7,577 |
| Pfizer | 16 | $6,746 |
| AstraZeneca | 19 | $4,576 |
| Boston Scientific | 15 | $1,549 |
| Lilly USA, LLC | 2 | $622 |
| Novartis | 51 | $555 |
| Johnson & Johnson(2 entities) | 18 | $368 |
| Boehringer Ingelheim | 11 | $237 |
| Amgen | 7 | $207 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $207 |
| Sanofi-aventis U.S. LLC | 7 | $164 |
| Regeneron Healthcare Solutions, Inc. | 5 | $80 |
| Novo Nordisk | 4 | $64 |
| Medtronic | 1 | $54 |
| Portola Pharmaceuticals, LLC | 3 | $46 |
| Biotronik Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $29 |
| Abiomed | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Infobionic, Inc | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Abbott | 1 | $12 |
| Actelion Pharmaceuticals US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$13,999
- FARXIGA$4,322
- ROTABLATOR$1,004
- JARDIANCE$666
- POLARIS$118
How this compares
$23,238 in reported general payments places this provider in the 75th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 637 | $668,912 |
| EntrestoSacubitril/Valsartan | 164 | $188,856 |
| XareltoRivaroxaban | 104 | $112,038 |
| MultaqDronedarone Hcl | 25 | $25,285 |
| BrilintaTicagrelor | 19 | $12,650 |
| Metoprolol Succinate | 793 | $10,101 |
| Ranolazine ErRanolazine | 76 | $8,446 |
| Atorvastatin Calcium | 454 | $3,567 |
| Flecainide Acetate | 80 | $2,809 |
| Amiodarone Hcl | 80 | $2,795 |
| Bumetanide | 131 | $2,753 |
| Carvedilol | 357 | $2,654 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 102 | $2,239 |
| Rosuvastatin Calcium | 143 | $2,065 |
| Spironolactone | 252 | $1,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $6,746 | $668,912637 claims |
| NovartisEntresto | $555 | $188,856164 claims |
| Johnson & JohnsonXarelto | $368 | $112,038104 claims |
| Sanofi-aventis U.S. LLCMultaq | $164 | $25,28525 claims |
| AstraZenecaBrilinta | $4,576 | $12,65019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Oak Ridge
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Ayaz RahmanKnoxville$251K
- Samuel HorrNashville$246K
- Joseph WeinsteinMemphis$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.